SEARCH

SEARCH BY CITATION

References

  • 1
    Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003; 23: 2138.
  • 2
    Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 10091022.
  • 3
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001; 120: 18281853.
  • 4
    Rang A, Bruns M, Heise T, Will H. Antiviral activity of interferon-α against hepatitis B virus can be studied in non-hepatic cells and is independent of MxA. J Biol Chem 2002; 277: 76457647.
  • 5
    Peters M, Walling DM, Waggoner J, Avigan MI, Sjogren M, Hoofnagle JH. Immune effects of alpha-interferon in chronic liver disease. J Hepatol 1986; 3(Suppl 2): S283S289.
  • 6
    Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone, and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295301.
  • 7
    Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298305.
  • 8
    Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123129.
  • 9
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2A, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 10
    Fried MW, Lau GKK, Piratvisuth T, Luo KX, Chow WC, Paik SW, et al. Greater viral suppression with lamivudine ± peginterferon α-2a (Pegasys®) does not translate into improved rates of sustained HBeAg seroconversion: Results from a large, multinational study [Abstract]. J Hepatol 2005; 42(Suppl): 176.
  • 11
    Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut 2005; 54: 16041609.
  • 12
    Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pre-treatment viremia? HEPATOLOGY 2001; 34: 10211026.
  • 13
    Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 14
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998; 93: 896900.
    Direct Link:
  • 15
    Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH. Pilot study of recombinant human α-interferon for chronic type B hepatitis. Gastroenterology 1986; 90: 150157.
  • 16
    Niederau C, Heingtes T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14221427.
  • 17
    Lau DTY, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 16601667.
  • 18
    Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. HEPATOLOGY 2001; 34: 139145.
  • 19
    Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. HEPATOLOGY 2003; 37: 756763.
  • 20
    van Zonneveld M, Honkoop P, Hansen BE, Niesters HGM, Murad SD, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. HEPATOLOGY 2004; 39: 804810.
  • 21
    Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with or without lamivudine: Results of 4-year follow-up [Abstract]. J Hepatol 2008; 48(Suppl): S46.
  • 22
    Buster EHCJ, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 2008; 135: 459467.
  • 23
    Korevaar A, Moucari R, Asselah T, Lada O, Boyer N, Martinot-Peignoux M, et al. High rates of HBsAg seroconversion in chronic hepatitis B patients responding to interferon therapy: A long-term follow-up study [Abstract]. HEPATOLOGY 2007; 46(Suppl): 679A.
  • 24
    Manensis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101109.
  • 25
    Werle-Lapostelle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Presence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 17501758.
  • 26
    Chan H LY, Wong VW, Tse A ML, Tse C-H, Chim AML, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 14621468.
  • 27
    Sung JJY, Wong ML, Bowden S, Liew CT, Hui AY, Wong VWS, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 18901897.
  • 28
    Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 13181325.
  • 29
    Cooksley G, Manns M, Lau GKK, Liaw YF, Marcellin P, Chow WC, et al. Effect of genotype and other baseline factors on response to peginterferon α-2a (40 kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: Results from a large, randomised study [Abstract]. J Hepatol 2005; 42: 3031.
  • 30
    Erhardt A, Ludwig AD, Brunetto M, van Boemmel F, Wolf E, Goebel T, et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients [Abstract]. HEPATOLOGY 2008; 48(Suppl): 700A.
  • 31
    Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699705.
  • 32
    Erhardt A, Reineke U, Blondin G, Gerlich WH, Adams O, Heintges T, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. HEPATOLOGY 2000; 31: 716725.
  • 33
    Sanchez-Tapias JM, Costa J, Mas A, Brugera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology 2002; 123: 18481856.
  • 34
    Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 10091013.
  • 35
    Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HLA. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297303.
    Direct Link:
  • 36
    Brunetto M, Bonino F, Moriconi F, Marcellin P, Lau GK, Farci P, et al. Significant reduction of HBsAg in the sera of HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a, alone or in combination with lamivudine [Abstract]. HEPATOLOGY 2006; 44(Suppl): 549A.
  • 37
    Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from the explorative analysis of published evidence. Antivir Ther 2008; 13: 211220.
  • 38
    Hou J, Schilling R, Janssen HLA, Hansen BE, Heijtink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 2007; 79: 10551063.
  • 39
    Radecke K, Protzer U, Trippler M, Meyer zum Buschenfelde KH, Gerken G. Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-α therapy. J Med Virol 2000; 62: 479486.
  • 40
    Manensis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 7382.
  • 41
    Gish RG, Lau DTY, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 27182723.
    Direct Link:
  • 42
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, HEPATOLOGY 2008; doi 10.1002/hep.22744.
  • 43
    Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels—a guide to sustained response to pegylated interferon alfa-2a in HBeAg-negative patients. HEPATOLOGY 2009; 49: 11411151.
  • 44
    Chan HLY, Wong VW, Wong GLH, Chim AML, Chan HY, Sung JJY. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008; 6: 10221026.
  • 45
    Fried MW, Piratvisuth T, Lau GKK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. HEPATOLOGY 2008; 47: 428434.
  • 46
    Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, et al. Early HBsAg loss during peginterferon alpha-2b therapy predicts HBsAg-loss- Results of a long-term follow-up study in chronic hepatitis B [Abstract]. HEPATOLOGY 2008; 48: 723A.
  • 47
    Piratvisuth T, Luo K-X, Marcellin P, Chang W-Y, Berg T, Flisiak R, et al. Effect of ALT flares on efficacy and safety of peginterferon α-2a (40 kDa) (Pegasys®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B [Abstract]. J Hepatol 2005; 42: 189.
  • 48
    Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 11161121.
  • 49
    Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908916.
  • 50
    Lok ASF, McMahon BJ. AASLD Practice Guidelines: Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 51
    Buster EHC, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, et al. Peginterferon alfa-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. HEPATOLOGY 2007; 46: 388394.
  • 52
    Marcellin P, Lau GKK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 477485.
  • 53
    Carta MG, Hardoy MC, Garofalo A, Pisano E, Nonnoi V, Intilla G, et al. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemiol Ment Health 2007; 3: 2225.
  • 54
    Perrillo RP. Therapy of hepatitis B—viral suppression or eradication? HEPATOLOGY 2006; 43(Suppl.): S182S193.
  • 55
    Buster EHCJ, Janssen HLA. Antiviral treatment for chronic hepatitis B virus infection-immune modulation or viral suppression? Neth J Med 2006; 64: 175185.